Clinical Trial Update: A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating dulanermin with the FOLFOX regimen and bevacizumab for previously untreated locally advanced, recurrent, or metastatic colorectal cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Dulanermin (rhApo2L) (dulanermin)

Snippet

Sponsor: Genentech, Inc. | Conditions: Metastatic Colorectal Cancer | Phase 1 | Status: COMPLETED